stockrow
Friday 6 November 2026
Export PHVS’s income statement to Excel — free account
Pharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
34.81
2.28
+7.01%
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) Total debt
Pharvaris N.V.'s total debt at the end of fiscal 2025 was $652.3K, down 5.67% from $691.5K in fiscal 2024. At the end of the quarter to 30 June 2026 it was $559.6K. Over the past ten years it has ranged from $47.1K (fiscal 2023) to $691.5K (fiscal 2024); the current reading is higher than 80% of that period. Pharvaris N.V. ranks 418th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $652.3K | (5.67%) |
| FY2024 | $691.5K | 1,368.15% |
| FY2023 | $47.1K | (82.08%) |
| FY2022 | $262.8K | 47.31% |
| FY2021 | $178.4K | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $559.6K | (10.22%) |
| Mar 2026 | $623.3K | (4.45%) |
| Dec 2025 | $652.3K | 26.54% |
| Sep 2025 | $515.5K | (3.91%) |
| 17 more quarters | Free account |
Against its own ten years
Low $47.1K
High $691.5K
Ten-year median
$262.8K
Current reading's percentile
80
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| ADMA ADMA Biologics Inc compare | $198.9M |
| VCEL Vericel Corporation compare | $85.1M |
| PVLA Palvella Therapeutics, Inc. compare | $12.3M |
| CLDX Celldex Therapeutics, Inc. compare | $1.2M |
| PHVS Pharvaris N.V. | $559.6K |
| IMNM Immunome, Inc. compare | $228.0K |
| NAMS NewAmsterdam Pharma Company N.V. compare | $94.9K |
| RXRX Recursion Pharmaceuticals, Inc. compare | $93.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt